Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00261170 · ClinicalTrials.gov registry record · Phase 3
Bupropion for Hospital-Based Smoking Cessation
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 85
- Enrollment target
NCT00261170 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 85 participants.
The verdict
NCT00261170, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is a randomized blinded trial of whether hospitalized smokers who are randomly assigned to receive bupropion, an antidepressant, and cognitive-behavioral counseling, are more likely to have quit smoking at the end of treatment and at 6 months compared with smokers randomly assigned to receive placebo and cognitive-behavioral counseling. Because depression is more prevalent among smokers and because smokers who are prone to depression may become depressed when they quit, the hypothesis is that the proportion of quitters who receive the active drug/antidepressant will be greater than the proportion of quitters who receive the placebo drug at 6 months.
Interventions
- OTHER placebo
- DRUG bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2003-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00261170
The ClinicalTrials.gov registry entry for NCT00261170 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00261170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00261170 about?
NCT00261170 is a clinical study titled "Bupropion for Hospital-Based Smoking Cessation". This is a randomized blinded trial of whether hospitalized smokers who are randomly assigned to receive bupropion, an antidepressant, and cognitive-behavioral counseling, are more likely to have quit smoking at the end of treatment and at 6 months compared with smokers randomly assigned to receive p...
What is the current status of trial NCT00261170?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 85 participants. The study started on 2003-07. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00261170?
The interventions under investigation include: placebo (OTHER), bupropion (DRUG).
Who is sponsoring clinical trial NCT00261170?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.